Cargando…

Aperiodic neural activity is a biomarker for depression severity

A reliable physiological biomarker for Major Depressive Disorder (MDD) is necessary to improve treatment success rates by shoring up variability in outcome measures. In this study, we establish a passive biomarker that tracks with changes in mood on the order of minutes to hours. We record from intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hacker, C., Mocchi, M.M, Xiao, J., Metzger, B.A., Adkinson, J.A., Pascuzzi, B.R., Mathura, R.C., Oswalt, D., Watrous, A., Bartoli, E., Allawala, A., Pirtle, V., Fan, X., Danstrom, I., Shofty, B., Banks, G., Zhang, Y., Armenta-Salas, M., Mirpour, K., Provenza, N., Mathew, S., Cohn, J., Borton, D., Goodman, W., Pouratian, N., Sheth, S.A., Bijanki, K.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659509/
https://www.ncbi.nlm.nih.gov/pubmed/37986996
http://dx.doi.org/10.1101/2023.11.07.23298040
Descripción
Sumario:A reliable physiological biomarker for Major Depressive Disorder (MDD) is necessary to improve treatment success rates by shoring up variability in outcome measures. In this study, we establish a passive biomarker that tracks with changes in mood on the order of minutes to hours. We record from intracranial electrodes implanted deep in the brain – a surgical setting providing exquisite temporal and spatial sensitivity to detect this relationship in a difficult-to-measure brain area, the ventromedial prefrontal cortex (VMPFC). The aperiodic slope of the power spectral density captures the balance of activity across all frequency bands and is construed as a putative proxy for excitatory/inhibitory balance in the brain. This study demonstrates how shifts in aperiodic slope correlate with depression severity in a clinical trial of deep brain stimulation for treatment-resistant depression (TRD). The correlation between depression severity scores and aperiodic slope is significant in N=5 subjects, indicating that flatter (less negative) slopes correspond to reduced depression severity, especially in the ventromedial prefrontal cortex. This biomarker offers a new way to track patient response to MDD treatment, facilitating individualized therapies in both intracranial and non-invasive monitoring scenarios.